Genfit S.A. (EPA: GNFT)
France
· Delayed Price · Currency is EUR
3.460
-0.040 (-1.14%)
Dec 20, 2024, 5:35 PM CET
Genfit Revenue
Genfit had revenue of 61.10M EUR in the half year ending June 30, 2024, with 403.23% growth. This brings the company's revenue in the last twelve months to 80.47M, up 175.45% year-over-year. In the year 2023, Genfit had annual revenue of 34.48M with 31.38% growth.
Revenue (ttm)
80.47M
Revenue Growth
+175.45%
P/S Ratio
2.14
Revenue / Employee
476.18K
Employees
159
Market Cap
172.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
Dec 31, 2019 | 38.97M | 31.61M | 429.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech S.A. | 2.74B |
bioMérieux S.A. | 3.81B |
Eurofins Scientific SE | 6.72B |
Ipsen S.A. | 3.44B |
Virbac SA | 1.34B |
Ramsay Générale de Santé SA | 5.01B |
Genfit News
- 4 weeks ago - Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions - Seeking Alpha
- 5 weeks ago - GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 - GlobeNewsWire
- 6 weeks ago - Genfit reports 9M results - Seeking Alpha
- 6 weeks ago - GENFIT Reports Third Quarter 2024 Financial Information - GlobeNewsWire
- 3 months ago - Top 4 Health Care Stocks That May Keep You Up At Night - Benzinga
- 3 months ago - GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval - GlobeNewsWire
- 3 months ago - Genfit GAAP EPS of €0.53, revenue of €61.2M - Seeking Alpha
- 5 months ago - GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis - GlobeNewsWire